Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs) - 05/11/12
Corresponding author. Tel.: +86 28 85422870; fax: +86 28 85424110.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 7 |
| Iconografia | 4 |
| Video | 0 |
| Altro | 0 |
Summary |
Background and objective |
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GISTs). To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed.
Methods |
Electronic search of the PubMed and EMBASE, which have articles published between 1980 and February 2012, was conducted to select studies for this meta-analysis.
Results |
Five articles with a total number 1861 of advanced GISTs patients were involved in this meta-analysis. There was a slight but significant 2-year PFS advantage with high-dose group (OR=1.25, 95% CIs=1.03–1.52, P=0.03), but not in the 2-year OS (OR=1.02, 95% CIs=0.84–1.24, P=0.87), CR (OR=1.02, 95% CIs=0.66–1.58, P=0.93), and PR (OR=1.13, 95% CIs=0.94–1.36, P=0.20). In safety, the high-dose group increased the incidence of above grade 3 toxicity (OR=2.05, 95% CIs=1.70–2.48, P<0.00001), particular in the blood toxicity, skin disorders, nausea and so on.
Conclusions |
This analysis confirms a slight 2-year PFS advantage of high-dose imatinib, but imatinib dose escalation could not lead to any other major clinical benefits, and brought more toxic effects for patients.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 36 - N° 5
P. 484-490 - Ottobre 2012 Ritorno al numero
Articolo precedente
- Aberrant expression of Wnt and Notch signal pathways in Barrett’s esophagus
- Xia Chen, Ke Jiang, Zhining Fan, Zheng Liu, Ping Zhang, Liduan Zheng, Na Peng, Jingjing Tong, Guozhong Ji
- Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity
- Serkan Torun, Bilge Demirel Tunc, Burak Suvak, Hakan Yildiz, Adnan Tas, Abdurrahim Sayilir, Yasemin Ozin Ozderin, Yavuz Beyazit, Ertugrul Kayacetin
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?